Low-frequency modulated electric current therapy has been recently evaluated for pain relief secondary to osteoarthritis and fibromyalgia [27,28,29] and, despite there being growing evidence of the therapeutic basis for NAT through parasympathetic nervous signal damping, the clinical experience with this form of therapy is still very limited. The gene discussed is BRD2; the disease is osteoarthritis.